Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

32.15 +0.75 (+2.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Earnings Preview For Liquidia ↗
 
Via Benzinga
News headline image
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
News headline image
These Analysts Boost Their Forecasts On Liquidia ↗
 
Via Benzinga
News headline image
Breaking Down Liquidia: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗
 
Via Benzinga
Topics Stocks
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Which stocks are gapping on Tuesday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge ↗
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics 
Via Benzinga
Topics Intellectual Property
News headline image
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod ↗
The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending. 
Via Stocktwits
Topics Intellectual Property
News headline image
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Where Liquidia Stands With Analysts ↗
 
Via Benzinga
News headline image
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
From Liquidia Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.